Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma. Read more about Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma.
Long-term patient-reported neurocognitive outcomes in adult survivors of hematopoietic cell transplant. Read more about Long-term patient-reported neurocognitive outcomes in adult survivors of hematopoietic cell transplant.
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia. Read more about Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia.
A genetically distinct pediatric subtype of primary CNS large B-cell lymphoma is associated with favorable clinical outcome. Read more about A genetically distinct pediatric subtype of primary CNS large B-cell lymphoma is associated with favorable clinical outcome.
Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. Read more about Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma.
Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Read more about Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib.
Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models. Read more about Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models.
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Read more about Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy.
Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy. Read more about Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy.
Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma. Read more about Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma.
